types of cryptocurrency pdf Block

Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.According to the weekly comprehensive price quotation and transaction information of the national carbon market, the comprehensive price quotation of the national carbon market this week is: the highest price is 102.03 yuan/ton, and the lowest price is 98.95 yuan/ton, and the closing price is 0.20% lower than last Friday. This week, the transaction volume of the listing agreement was 4,455,200 tons, with a turnover of 443,893,910.63 yuan; The volume of bulk agreement transactions was 35,748,795 tons, with a turnover of 353,449,4051.32 yuan. This week, the total turnover of the national carbon emission quota was 40,203,995 tons, with a total turnover of 397,877,961.95 yuan. From January 1 to December 13, 2024, the volume of carbon emission quota in the national carbon market was 169,736,665 tons, with a turnover of 162,864,7748.47 yuan. As of December 13, 2024, the cumulative turnover of carbon emission quotas in the national carbon market was 611,359,276 tons, with a cumulative turnover of 412,056,282,67.75 yuan. (National Carbon Trading)Minsheng Bank: New Hope Chemical was approved to increase its shareholding by no more than 68 million shares. Minsheng Bank announced that the State Financial Supervision and Administration Bureau approved New Hope Chemical Investment Co., Ltd. to increase its shareholding in Minsheng Bank by no more than 68 million shares through the secondary market within six months. After the completion of the increase, New Hope Chemical and its concerted actions will hold no more than 2.24 billion shares of Minsheng Bank, with a shareholding ratio of no more than 5.12%.

HKEx: HSBC repurchased 527,200 shares for HK$ 39.4 million on December 12.Digital authentication has set up a new technology company in Tianjin. The enterprise search APP shows that Tianjin Mixin Tianxing Technology Co., Ltd. was recently established, with Cheng Xiaozhuo as the legal representative and a registered capital of 30 million yuan. Its business scope includes: electronic authentication services; Software development; Information system integration service; Network and information security software development, etc. Enterprise equity penetration shows that the company is wholly owned by Digital Certification.Market News: It is reported that Morgan Stanley will buy a mortgage loan from Santander Bank, worth about 900 million euros.

Before the US stock market: China ETF-Direxion fell by nearly 4% and Broadcom rose by about 14% when it was three times richer. Before the US stock market, China Stock Exchange fell by about 3% and Pinduoduo fell by about 1%. Broadcom rose by about 14%, the company's Q4 profit exceeded expectations, and AI revenue in the whole fiscal year doubled by 220%.Azure lithium battery: Robot/dog is the application field of lithium battery that the company pays close attention to. At present, only a few shipments are used in this field. Robot/dog is the application field of lithium battery that the company pays close attention to. At present, only a few shipments are used in this field, accounting for a small proportion. At present, power tools, cleaning appliances and electric motorcycles are the main applications.Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.